At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b clinical trial that evaluated the safety and clinical activity of avelumab, a fully human anti-PD-L1 IgG1 antibody, for the treatment of patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer
14 Oct 2015
Oncology
